Kwang Dong Pharmaceutical Co., Ltd. (KRX:009290)
South Korea · Delayed Price · Currency is KRW 6,290.00
-10.00 (-0.16%)
At close: Jun 16, 2026
Kwang Dong Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,692,762 | 1,659,512 | 1,640,719 | 1,514,454 | 1,431,545 | 1,338,182 |
Other Revenue | - | - | - | - | - | -0 |
| 1,692,762 | 1,659,512 | 1,640,719 | 1,514,454 | 1,431,545 | 1,338,182 | |
Revenue Growth (YoY) | 5.41% | 1.15% | 8.34% | 5.79% | 6.98% | 7.59% |
Cost of Revenue | 1,385,500 | 1,360,558 | 1,343,737 | 1,216,563 | 1,151,550 | 1,065,870 |
Gross Profit | 307,263 | 298,955 | 296,982 | 297,891 | 279,995 | 272,312 |
Selling, General & Admin | 251,406 | 249,309 | 246,225 | 233,331 | 225,167 | 213,458 |
Research & Development | 9,636 | 9,131 | 10,128 | 15,275 | 9,678 | 8,322 |
Amortization of Goodwill & Intangibles | 1,384 | 1,187 | 1,024 | 473.49 | 1,233 | 1,185 |
Other Operating Expenses | 1,676 | 1,522 | 2,059 | 1,989 | 1,391 | 1,589 |
Operating Expenses | 272,004 | 267,909 | 266,885 | 255,821 | 241,751 | 227,376 |
Operating Income | 35,259 | 31,046 | 30,097 | 42,070 | 38,244 | 44,936 |
Interest Expense | -11,161 | -11,005 | -10,274 | -6,904 | -3,735 | -2,544 |
Interest & Investment Income | 5,547 | 4,954 | 6,319 | 5,399 | 2,844 | 2,415 |
Earnings From Equity Investments | -7,082 | -11,441 | 767.76 | -429.82 | -435.51 | -112.22 |
Currency Exchange Gain (Loss) | -9.53 | -1,516 | 3,159 | -384.81 | 6.49 | 693.27 |
Other Non Operating Income (Expenses) | 60.22 | 1,403 | -1,169 | -179.12 | 1,132 | -865.71 |
EBT Excluding Unusual Items | 22,613 | 13,441 | 28,900 | 39,571 | 38,056 | 44,522 |
Gain (Loss) on Sale of Investments | 6,229 | 7,050 | 25,399 | 9,412 | -1,932 | -10,232 |
Gain (Loss) on Sale of Assets | 660.96 | 7,677 | 3,026 | -1,964 | 166.52 | 38.87 |
Asset Writedown | -2,590 | -2,590 | - | - | - | - |
Pretax Income | 32,319 | 30,985 | 57,325 | 49,019 | 36,291 | 34,329 |
Income Tax Expense | 10,150 | 9,656 | 15,480 | 9,648 | 9,590 | 8,788 |
Earnings From Continuing Operations | 22,168 | 21,329 | 41,845 | 39,372 | 26,701 | 25,541 |
Minority Interest in Earnings | -546.44 | -360.35 | -1,364 | -2,406 | -2,527 | -1,522 |
Net Income | 21,622 | 20,968 | 40,481 | 36,966 | 24,174 | 24,019 |
Net Income to Common | 21,622 | 20,968 | 40,481 | 36,966 | 24,174 | 24,019 |
Net Income Growth | -16.93% | -48.20% | 9.51% | 52.91% | 0.65% | -47.06% |
Shares Outstanding (Basic) | 43 | 40 | 40 | 40 | 41 | 41 |
Shares Outstanding (Diluted) | 43 | 40 | 40 | 40 | 41 | 41 |
Shares Change (YoY) | 7.43% | 0.50% | -1.06% | -1.48% | -0.11% | 1.48% |
EPS (Basic) | 505.28 | 521.09 | 1011.00 | 913.39 | 588.45 | 584.68 |
EPS (Diluted) | 504.35 | 521.09 | 1011.00 | 913.00 | 588.00 | 584.33 |
EPS Growth | -22.72% | -48.46% | 10.73% | 55.27% | 0.63% | -47.78% |
Free Cash Flow | 30,508 | 52,479 | -87,883 | -46,515 | 37,439 | 31,145 |
Free Cash Flow Per Share | 712.00 | 1304.16 | -2194.85 | -1149.35 | 911.36 | 757.27 |
Dividend Per Share | - | - | - | - | 100.000 | 100.000 |
Gross Margin | 18.15% | 18.02% | 18.10% | 19.67% | 19.56% | 20.35% |
Operating Margin | 2.08% | 1.87% | 1.83% | 2.78% | 2.67% | 3.36% |
Profit Margin | 1.28% | 1.26% | 2.47% | 2.44% | 1.69% | 1.80% |
Free Cash Flow Margin | 1.80% | 3.16% | -5.36% | -3.07% | 2.61% | 2.33% |
EBITDA | 54,798 | 49,101 | 44,629 | 54,974 | 52,262 | 59,045 |
EBITDA Margin | 3.24% | 2.96% | 2.72% | 3.63% | 3.65% | 4.41% |
D&A For EBITDA | 19,540 | 18,055 | 14,532 | 12,904 | 14,017 | 14,110 |
EBIT | 35,259 | 31,046 | 30,097 | 42,070 | 38,244 | 44,936 |
EBIT Margin | 2.08% | 1.87% | 1.83% | 2.78% | 2.67% | 3.36% |
Effective Tax Rate | 31.41% | 31.16% | 27.00% | 19.68% | 26.43% | 25.60% |
Advertising Expenses | - | 42,261 | 45,513 | 46,186 | 42,214 | 40,464 |